William Werbel MD PhD

The Emerging Pathogens of Concern (EPOC) research study (IRB0038184; Principal Investigator Dr. William Werbel) is live, studying infections & vaccines in immunocompromised persons & close contacts. Visit emergingpathogens.jhmi.edu or email emergingpathogens@jh.edu for more info!

US CDC: a public health agency in critical condition - The Lancet thelancet.com/journals/lance…

Registration is OFFICIALLY open! 🥳 shorturl.at/xbJLd

#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. gilead.inc/4e9KI6B

Very proud of the 17 dismissed ACIP members for writing this together – Advisory Committee on Immunization Practices at a Crossroads | JAMA | JAMA Network jamanetwork.com/journals/jama/…

A bill to dissolve NIAID has been introduced in Congress. Start contacting your US legislators now! congress.gov/bill/119th-con…

Sanjat Kanjilal of Harvard Medical School joins JAMA Associate Editor Yulin Hswen to discuss the use of machine learning algorithms to assess the management of urinary tract infection and more. ja.ma/42W4Q8I

1/ After residency at Mass General Hospital, I reported to Atlanta to meet my fellow CDC Epidemic Intelligence Service Officers. I have never felt so intimidated by my peers The best and the brightest, they were star clinicians, had served in disaster zones; MD/PhDs and MSF.

@victoriahall26 @NEJM @PeterMacCC @NCICancer Congrats, Tori!

Very proud of this hard work by all involved. Limited benefit of adjuvanted flu vaccine vs standard dose and 2 vs 1 doses in patients with myeloma, CLL or NHL. @NEJM @PeterMacCC @NCICancer nejm.org/doi/full/10.10…

@MichaelGIsonMD @JAMA_current @Hopkins_TRC @AndrewKaraba @Dorry_Segev Thanks, Mike!

@HIV_TID @JAMA_current @Hopkins_TRC @AndrewKaraba @Dorry_Segev Great job! This is important work! So much to learn about vaccines in this population.

Ringing in 2025 with our work evaluating antibody response to RSV vaccines in immunocompromised persons in @JAMA_current (Editor's choice!). A preliminary product of our ongoing EPOC study (emergingpathogens.jhmi.edu) jamanetwork.com/journals/jama/… @Hopkins_TRC @AndrewKaraba @Dorry_Segev

New #LetsTalkID episode out now! Medical editors of the Real-Time Learning Network (@MatiH_ID, @Payal_Patel, @mariasundaram, @HIV_TID) recount their experiences building the project and discuss lessons learned for the future. Transcript: bit.ly/4fu1rRV

Study in @NEJM (bit.ly/3YuHjcs) led by @HopkinsMedicine provides strong evidence that #HIV-to-HIV transplants are as safe & effective as transplants using organs from donors w/o HIV. See bit.ly/40304Vt. @HopkinsTRC @hopkinssurgery @JHMed_ID #ChristineDurandMD

🚨 CRITICAL READ 🚨 If you do research in Transplant ID, this paper is a MUST read. From @CMDurandMD and the @Hopkins_TRC a brilliant blueprint in how to build a successful transplant research center. From @TheTxIDjournal onlinelibrary.wiley.com/doi/10.1111/ti…

🫡

Thank you for featuring this insightful work led by @MayanTeles @ Janetta Brundage.

Introducing the 2024 Pilot Research Awardees! 🤩 Huge congrats to Patricia Bloom, MD. Learn more about AASLD Foundation's 2024 awardees at aasldfoundation.org/2024-research-…

Definitionally re: reinfections, 1st had to have occurred earlier (in less immune state), ? complicated by persistent or later "exacerbatable" sequelae. Also ? link between heavier immunosuppression and reinfection risk post vaccination. Regardless, data support 💉 in this group.

≥1 symptom reported by 30%, widely varying phenotypes (subgroup with symptoms in all 5 domains). This was following mild infections, majority post vaccination in Omicron era. Pre-infxn vaccination appeared protective! Whereas reinfections might be risk for #PASC.

Great work @MayanTeles @janettabrundage @TeresaChiangMD in assessing post-acute COVID aka #longcovid prevalence, syndromes, and risk factors in persons with autoimmune/rheumatic conditions leveraging our national prospective cohort. pubmed.ncbi.nlm.nih.gov/38950954/ @JHMed_ID @Hopkins_TRC